Antibacterial Agents TRIZ Cases

A pharmaceutical composition induces M1 macrophage polarization to inhibit Mycobacterium tuberculosis survival.

Lactobacillus rhamnosus GG lysate inhibits Staphylococcus aureus growth and adhesion to keratinocytes through competitive exclusion mechanisms.

Purified 25-desacetyl rifaximin overcomes bacterial resistance in bowel disorder treatment.

Specific bacteriophage strains lyse resistant pathogens at the ulcer site, bypassing antibiotic resistance mechanisms.

A pharmaceutical composition combining Spirulina platensis, Magnolia officinalis extract, and mumie extract targets bacterial pathogens.

Adding acid to the 1,4-bis-dimethylamino-2-butene and triethanolamine mixture reduces degraded impurities and increases yield.

Alkane diols combined with tropolone resolve the contradiction between broad-spectrum coverage and rapid efficacy, achieving 3 log10 virucidal reduction.

Steroid alkaloids inhibit bacterial ATP synthase subunit C to potentiate aminoglycosides against electron transport-deficient bacteria.

Cinnamic acid and osthole extracts in toothpaste provide antibacterial action against oral pathogens.

Cyclodextrin mediates triclosan solubility and foaming performance, resolving incompatibility with potassium salts in desensitizing toothpaste.

Specific compounds modulate CCR2 and CCR5 activity to reduce leukocyte recruitment, addressing side effects from traditional inflammatory treatments.

BTN3A activating antibodies enhance Vγ9Vδ2 T cell responses to reduce viral and bacterial loads in infectious disorders.

Specific lactic acid bacterial strains inhibit Escherichia coli growth, reducing icteric index and irradiation hours for infant jaundice treatment.

Multiarm polymer reagents with terminal hydroxyapatite-targeting moieties bind to bone surfaces, preventing polymer chain wrapping that limits ligand access.

Formula I compounds inhibit AKT kinases to treat hyperproliferative diseases like cancer.

Enterococcus polypeptides induce opsonic antibodies to eliminate pathogens, bypassing antibiotic resistance development.

Cationic liposome delivery vehicles transport non-coding DNA plasmids to stimulate embryonic immune systems in avian species.

Fusing bacteriocin binding domains with lysin enzymes creates stable chimeric polypeptides targeting Gram-positive bacteria.

Topical tyrosine-derived polyesteramide delivers sustained minocycline release to inhibit bacterial colonization at median sternotomy sites.

Aptamers targeting the P97 adhesin replace variable antibiotics, blocking Mycoplasma hyopneumoniae binding to host cilia.

A synbiotic composition combines specific probiotic strains with prebiotics to colonize intestinal mucosa and stimulate beneficial bacterial growth.

Colloidal silica carriers increase antibiotic concentration in infected tissues, resolving insufficient therapeutic efficacy against resistant microbes.

Plant-derived steroid synthesis produces high-purity bile acids free from animal pathogens, resolving contamination risks.

Colpeptin1 peptides induce bacterial protein aggregation, resolving antibiotic resistance by triggering proteostatic collapse without harming mammalian cells.

Formula I diaminopyrimidines modulate P2X3 and P2X2/3 receptors to treat genitourinary disorders with improved pharmacokinetics.

LXRβ agonists reduce myeloid derived suppressor cells to overcome T-cell suppression and improve immunotherapy response rates.

Compounds of Formula 1 and 2 inhibit channel activating proteases, resolving the lack of effective inhibitors for abnormal fluid regulation.

Linear ultrashort lipopeptides disrupt bacterial cell membranes through electrostatic and hydrophobic interactions to kill pathogens.

Benzonaphthyridine adjuvants strengthen subunit vaccine efficacy by bridging safe antigens with robust immune protection.

Modifying polyamine chains in squalamine analogs reduces cytotoxicity while maintaining efficacy against Gram-negative bacteria.

A solid coated carrier immobilizes antibodies within a protective matrix, preventing systemic side effects while maintaining therapeutic safety.

Cyclopropanated fatty acids stabilize unstable signaling factors to disperse biofilms and restore antibiotic sensitivity.

Disrupted Mycobacterium tuberculosis strains stimulate immune responses through targeted genetic modifications.

Substituted N,N-dihaloamine compounds inhibit bacterial, fungal, and viral growth through targeted molecular structures.

High-dose minocycline regimens overcome antibiotic resistance in carbapenem-resistant Acinetobacter baumannii and Escherichia coli infections.

Nekka-Rich oak bark extract composition prevents and treats intestinal infections caused by enterotoxigenic Escherichia coli in humans and animals.

Enriching antibody populations with altered Fab region sialylation using Sambucus nigra agglutinin affinity chromatography.

Lipid bilayer-coated metal organic framework nanoparticles transport NAD+ across cell membranes to replenish intracellular levels.

Aminoglycoside derivatives featuring 5-fluoro and guanidine groups overcome enzymatic inactivation by ESKAPE bacteria while reducing systemic toxicity.

GPR119 agonists stimulate endogenous GIP secretion to promote bone formation, bypassing poor oral bioavailability of direct peptide administration.

Substituted quinazolin-4-one compounds inhibit PI3K delta and gamma isoforms, avoiding blood-brain barrier penetration to reduce peripheral side effects.

Garlic extract combined with bioflavonoids and organic acids creates a synergistic antimicrobial composition.

Micronized placental tissue creams with aloe and allantoin enhance wound healing efficacy while reducing treatment costs.

Thiazole derivatives target PI3K alpha and gamma isoforms to resolve the contradiction between broad pathway inhibition and precise therapeutic effectiveness.